Pfizer and Moderna win FDA nod for XBB.1.5 COVID-19 vaccine boosters, but projected sales pale in comparison to 2022’s

As Pfizer and Moderna receive the FDA nod for COVID-19 boosters, their 2023 global sales projections appear to be just a fraction of the previous year’s. In 2022, Pfizer and its partner BioNTech jointly sold $56 billion worth of their Comirnaty COVID-19 vaccine, marking the best-selling drug of the year. Moderna’s Spikevax COVID-19 vaccine wasn’t far behind, registering sales of $18.4 billion, signifying the fifth best-selling drug.

After the FDA nod for COVID-19 boosters, market projections remain subdued

Demand for COVID-19 vaccines, however, appears to be relatively weak, a reality reflected in revenue guidance from Pfizer and Moderna. The former announced in its Q2 2023 revenue guidance that it projects its COVID-19 vaccine sales of approximately $13.5 billion — a 64% slide from its respective 2022 global sales of $37.8 billion. Meanwhile, Moderna expects its 2023 COVID-19 vaccine sales in the range of $6 billion to $8 billion.

A simple li…

Read more
  • 0